Welcome to our dedicated page for Lakefront Biotherapeutics NV SEC filings (Ticker: LKFT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lakefront Biotherapeutics NV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lakefront Biotherapeutics NV's regulatory disclosures and financial reporting.
Lakefront Biotherapeutics and Gilead Sciences have completed the acquisition of Ouro Medicines, adding the T cell engager gamgertamig (OM336) to their autoimmune pipelines. Gilead acquired all Ouro equity for $1,675 million plus up to $500 million in milestones, with Lakefront and Gilead splitting these payments equally.
Gamgertamig is a BCMAxCD3 T cell engager in Phase 2 with U.S. FDA Fast Track and Orphan Drug Designations and is expected to enter registrational studies as early as 2027. Lakefront takes on Phase 1/2 development while Gilead leads later-stage and commercialization, paying Lakefront tiered royalties of 20%–23% on net sales.
Lakefront also in-licensed three preclinical autoimmune programs with a Gilead opt-in for $75 million per program and a 50/50 profit split post proof-of-concept. The deal modifies the existing OLCA, allowing Lakefront to deploy at least $500 million of its cash independently, including up to $150 million for share buybacks, and the company expects a year-end 2026 cash balance of about €2B.